MCID: ANG020
MIFTS: 56

Angiosarcoma

Categories: Cardiovascular diseases, Fetal diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Angiosarcoma

MalaCards integrated aliases for Angiosarcoma:

Name: Angiosarcoma 12 76 59 37 55 6 15 40
Hemangiosarcoma 12 44 73

Characteristics:

Orphanet epidemiological data:

59
angiosarcoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0001816
MeSH 44 D006394
NCIt 50 C3088 C9275
Orphanet 59 ORPHA263413
UMLS via Orphanet 74 C0018923
ICD10 via Orphanet 34 C49.9
KEGG 37 H01666

Summaries for Angiosarcoma

Disease Ontology : 12 A malignant Vascular tumor that results in rapidly proliferating, extensively infiltrating anaplastic cells derives from blood vessels and derived_from the lining of irregular blood-filled spaces.

MalaCards based summary : Angiosarcoma, also known as hemangiosarcoma, is related to liver angiosarcoma and intravascular papillary endothelial hyperplasia. An important gene associated with Angiosarcoma is FLT4 (Fms Related Tyrosine Kinase 4), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Ethiodized oil and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and bone, and related phenotypes are Decreased cell migration and Increased senescence-associated beta-galactosidase protein expression after pRB stimulation

Wikipedia : 76 Angiosarcoma is a cancer of the cells that line the walls of blood vessels or lymphatic vessels. The... more...

Related Diseases for Angiosarcoma

Diseases related to Angiosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 320)
# Related Disease Score Top Affiliating Genes
1 liver angiosarcoma 34.1 KRAS VIM VWF
2 intravascular papillary endothelial hyperplasia 32.8 VEGFA VIM
3 epithelioid hemangioendothelioma 32.3 FLT1 KDR PECAM1 VEGFA
4 lymphangiosarcoma 32.1 FLT4 MYC PROX1 VEGFA VWF
5 hemangioendothelioma 31.6 FLI1 FLT4 KDR PECAM1
6 pyogenic granuloma 30.0 TEK VEGFA
7 benign breast phyllodes tumor 29.9 KIT VIM
8 malignant peripheral nerve sheath tumor 29.6 KIT MUC1 VIM
9 cystadenocarcinoma 29.4 MUC1 VEGFA VIM
10 perivascular epithelioid cell tumor 29.3 KIT MUC1 VIM
11 gastrointestinal stromal tumor 29.2 KIT KRAS VEGFA VIM
12 cavernous hemangioma 29.1 KDR KIT MUC1 VIM
13 adenocarcinoma 28.7 KDR KIT KRAS MUC1 VEGFA
14 pulmonary hypertension 28.6 FLT1 TEK VEGFA VWF
15 epithelioid sarcoma 28.5 KRT8 MUC1 VIM
16 hemangioma 28.4 FLT4 KDR KRAS PECAM1 PROX1 TEK
17 breast cancer 25.4 FLT1 FLT4 KDR KIT KRAS KRT8
18 breast angiosarcoma 12.3
19 spleen angiosarcoma 12.2
20 thyroid angiosarcoma 12.2
21 pediatric angiosarcoma 12.2
22 aorta angiosarcoma 12.2
23 skin angiosarcoma 12.2
24 angiosarcoma of the scalp 12.2
25 prostate angiosarcoma 12.2
26 gallbladder angiosarcoma 12.1
27 mediastinum angiosarcoma 12.0
28 ovarian angiosarcoma 12.0
29 conventional angiosarcoma 12.0
30 radiation induced angiosarcoma of the breast 12.0
31 central nervous system angiosarcoma 12.0
32 superior vena cava angiosarcoma 11.9
33 bone angioendothelial sarcoma 11.2
34 pseudoangiomatous stromal hyperplasia 10.8
35 hemifacial spasm 10.8 FLT4 VEGFA
36 lymphatic malformations 10.7 FLT4 PROX1
37 glomeruloid hemangioma 10.7 FLT1 VEGFA
38 hepatic angiomyolipoma 10.6 KIT MYC
39 female reproductive organ cancer 10.6 KRAS MYC VEGFA
40 respiratory system cancer 10.6 KRAS MYC VEGFA
41 arteriovenous malformations of the brain 10.6 KDR KRAS VEGFA
42 apocrine adenoma 10.5 KRAS MUC1
43 radiation proctitis 10.5 KDR PECAM1 VEGFA
44 angiokeratoma circumscriptum 10.5 FLT1 KDR VEGFA
45 mast-cell sarcoma 10.5 KIT VIM
46 infiltrating angiolipoma 10.5 VEGFA VWF
47 critical limb ischemia 10.5 VEGFA VWF
48 hydrocele 10.5 FLT4 PECAM1 VEGFA
49 hemangioma, capillary infantile 10.5 FLT4 KDR
50 acute hemorrhagic leukoencephalitis 10.5 FLT1 KDR VEGFA

Graphical network of the top 20 diseases related to Angiosarcoma:



Diseases related to Angiosarcoma

Symptoms & Phenotypes for Angiosarcoma

GenomeRNAi Phenotypes related to Angiosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.35 FLT1 KDR KRAS MUC1 VIM
2 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.8 FLT1 KIT TEK

MGI Mouse Phenotypes related to Angiosarcoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 MYC KRAS PECAM1 KRT8 FLT4 FLI1
2 hematopoietic system MP:0005397 10.32 KRT8 MYC KRAS PECAM1 KIT FLI1
3 homeostasis/metabolism MP:0005376 10.31 KIT KRT8 MYC KRAS FLT4 KDR
4 cellular MP:0005384 10.3 KIT MYC KRAS FLI1 KDR FLT1
5 immune system MP:0005387 10.29 KRT8 MYC KRAS KIT FLT4 FLI1
6 embryo MP:0005380 10.28 KRT8 MYC KRAS KIT FLT4 FLI1
7 growth/size/body region MP:0005378 10.26 KIT KRT8 MYC KRAS FLT4 FLI1
8 mortality/aging MP:0010768 10.25 KIT KRT8 MYC KRAS FLT4 FLI1
9 digestive/alimentary MP:0005381 10.2 KRT8 MYC KRAS KIT FLT4 PECAM1
10 muscle MP:0005369 10.18 MYC KRAS PECAM1 KIT FLT4 FLI1
11 liver/biliary system MP:0005370 10.16 KRT8 MYC KRAS KIT FLT4 FLI1
12 nervous system MP:0003631 10.11 KIT MYC KRAS FLI1 KDR FLT1
13 normal MP:0002873 9.91 KIT MYC KRAS FLT4 KDR FLT1
14 no phenotypic analysis MP:0003012 9.87 KIT MYC KRAS FLT4 KDR VEGFA
15 reproductive system MP:0005389 9.76 KRT8 KIT MYC KRAS FLT4 FLT1
16 respiratory system MP:0005388 9.5 KIT KRAS KDR PECAM1 VEGFA PROX1
17 vision/eye MP:0005391 9.23 KIT KRAS KDR FLT1 VEGFA PROX1

Drugs & Therapeutics for Angiosarcoma

Drugs for Angiosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
4
Mechlorethamine Approved, Investigational Phase 3,Phase 1 51-75-2 4033
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 2019 457193
10
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
11
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
12
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
13
Cyproheptadine Approved Phase 3 129-03-3 2913
14
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
18 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
20
Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
21 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
23 Etoposide phosphate Phase 3,Phase 2
24 Anti-Infective Agents Phase 3,Phase 2
25 Antimitotic Agents Phase 3,Phase 2
26 Antirheumatic Agents Phase 3,Phase 2,Phase 1
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
28 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
29 Antibodies Phase 3,Phase 2,Phase 1
30 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
31 Immunoglobulins Phase 3,Phase 2,Phase 1
32 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
33 Anti-Allergic Agents Phase 3
34 Antipruritics Phase 3
35 Dermatologic Agents Phase 3
36 Gastrointestinal Agents Phase 3
37 Histamine Antagonists Phase 3
38 Histamine H1 Antagonists Phase 3
39
Histamine Phosphate Phase 3 51-74-1 65513
40 Serotonin Agents Phase 3
41 Serotonin Antagonists Phase 3
42
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
43
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
44
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
45
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Bevacizumab Approved, Investigational Phase 2 216974-75-3
48
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
49
Gemcitabine Approved Phase 2 95058-81-4 60750
50
Everolimus Approved Phase 2 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
2 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
10 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
11 A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA Recruiting NCT02979899 Phase 3 Votrient
12 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
13 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery Unknown status NCT00874874 Phase 2 sorafenib tosylate
17 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
18 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
19 Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery Completed NCT01623869 Phase 2
20 Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery Completed NCT00217607 Phase 2 paclitaxel
21 Bevacizumab in Treating Patients With Angiosarcoma Completed NCT00288015 Phase 2
22 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
23 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
24 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
25 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
26 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
27 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
28 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
29 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
30 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
31 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
32 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
33 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
34 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
35 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
36 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
37 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
38 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
39 Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Recruiting NCT03331250 Phase 2 Eribulin
40 Evaluation of Votrient in Angiosarcoma Recruiting NCT02212015 Phase 2 Pazopanib + Paclitaxel
41 Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Recruiting NCT01462630 Phase 2 pazopanib hydrochloride
42 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Recruiting NCT02048722 Phase 2 regorafenib
43 Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Recruiting NCT03474094 Phase 2
44 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
45 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
46 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
47 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting NCT03414229 Phase 2 Epacadostat;Pembrolizumab
48 Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas Active, not recruiting NCT01303497 Phase 2 Paclitaxel;Bevacizumab
49 A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas Active, not recruiting NCT01140737 Phase 2 Axitinib
50 A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma Active, not recruiting NCT01975519 Phase 1, Phase 2 TRC105 and Pazopanib

Search NIH Clinical Center for Angiosarcoma

Cochrane evidence based reviews: hemangiosarcoma

Genetic Tests for Angiosarcoma

Anatomical Context for Angiosarcoma

MalaCards organs/tissues related to Angiosarcoma:

41
Breast, Liver, Bone, Lung, Endothelial, Thyroid, Spleen

Publications for Angiosarcoma

Articles related to Angiosarcoma:

(show top 50) (show all 958)
# Title Authors Year
1
Primary angiosarcoma of the femur in a patient with Takayasu arteritis. ( 29892593 )
2018
2
Mediastinal angiosarcoma presenting as diffuse alveolar hemorrhage. ( 29719795 )
2018
3
A Patient Presenting with Cardiac Tamponade and the Challenges of Finding Its Cause: A Cardiac Angiosarcoma. ( 29682355 )
2018
4
Impact of specialist management on survival from radiation-associated angiosarcoma of the breast. ( 29405251 )
2018
5
Treatment of cutaneous angiosarcoma of the scalp and face in Chinese patients: local experience at a regional hospital in Hong Kong. ( 29326400 )
2018
6
Novel Therapy for Pediatric Angiosarcoma With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. ( 29863582 )
2018
7
Jejunal angiosarcoma: a rare cause of obscure gastrointestinal bleeding with successful resection after enteroscopic localization. ( 29882282 )
2018
8
Primary Angiosarcoma of the Breast after Bilateral Breast Reduction. ( 29977639 )
2018
9
Early detection and integral resection are keys to extend survival in patients suffered from primary angiosarcoma of the spleen: A care-compliant case report and literature review. ( 29384853 )
2018
10
PD-L1-Expressing Radiation-Associated Angiosarcoma after Primary Breast Cancer. ( 29928212 )
2018
11
A rare autopsy case of epithelioid angiosarcoma arising in the aorta in a patient with massive multi-organ embolization. ( 29920855 )
2018
12
Clinical and Pathologic Features of Primary Angiosarcoma of the Kidney. ( 29383452 )
2018
13
Radiation-induced angiosarcoma of the omentum diagnosed by laparoscopy: A case report. ( 29399355 )
2018
14
Epithelioid angiosarcoma: A rare cause of pericarditis and pleural effusion. ( 29977765 )
2018
15
Gastrointestinal: Colonic angiosarcoma in a patient initially presenting with leg pain. ( 29943468 )
2018
16
Recurrent Cardiac Tamponade from Right Atrial Angiosarcoma. ( 29786059 )
2018
17
Response: Cardiac magnetic resonance in cardiac angiosarcoma-Which contrast-enhancement pattern is typical? ( 29409130 )
2018
18
Angiosarcoma associated with hypertrichosis. ( 29941407 )
2018
19
Cutaneous Angiosarcoma of the Eyelid Mimicking Morbihan Disease. ( 29329133 )
2018
20
Primary cardiac angiosarcoma: a rare cause of diffuse alveolar haemorrhage. ( 29866695 )
2018
21
Contrast uptake in primary hepatic angiosarcoma on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the hepatobiliary phase. ( 29399290 )
2018
22
Radiologic findings of primary pulmonary angiosarcoma: A case report. ( 29924006 )
2018
23
Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma. ( 29872503 )
2018
24
Primary Spleen Angiosarcoma With Concomitant Hepatic Hemangiomas on 18F-FDG PET/CT. ( 29356748 )
2018
25
Epithelioid Angiosarcoma Arising from a Huge Leiomyoma: A Case Report and a Literature Review. ( 29967705 )
2018
26
Hepatic Angiosarcoma with Kasabach-Merritt Phenomenon: A Case Report and Review of the Literature. ( 29893706 )
2018
27
Bilateral ovarian angiosarcoma arising from the mature cystic teratomas - A case report and review of the literature. ( 29227858 )
2018
28
Epithelioid Angiosarcoma: An Unusual Cause of Gastrointestinal Bleeding. ( 29944034 )
2018
29
Primary pulmonary epithelioid angiosarcoma: A case report and literature review. ( 29970720 )
2018
30
Computed Tomography-Guided Core Needle Biopsy of Cardiac Angiosarcoma. ( 29898050 )
2018
31
EXPRESS: Don't stop at first glance; pulmonary artery angiosarcoma mimicking chronic thromboembolic pulmonary hypertension. ( 29873586 )
2018
32
Cutaneous angiosarcoma in a patient with systemic sclerosis: First case from India. ( 29376512 )
2018
33
Angiosarcoma following treatment of basal cell carcinoma: a report of two cases. ( 29345300 )
2018
34
Angioinvasion as a factor for predicting aggressive outcome in primary thyroid angiosarcoma: three case reports and literature review. ( 29895127 )
2018
35
Mouse genetic background influences whether <i>Hras<sup>G12V</sup></i> expression plus <i>Cdkn2a</i> knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. ( 29731980 )
2018
36
Cardiac magnetic resonance in cardiac angiosarcoma-Which contrast-enhancement pattern is typical? ( 29409131 )
2018
37
Primary thyroid angiosarcoma: A systematic review. ( 29909901 )
2018
38
Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas. ( 28796347 )
2018
39
Radiation-associated Angiosarcoma Mimicking Fallopian Tube High-grade Serous Carcinoma in a Woman With De Novo Li-Fraumeni Syndrome. ( 29620582 )
2018
40
First report of proton beam therapy for breast angiosarcoma from the prospective PCG registry. ( 29303019 )
2018
41
Primary cardiac angiosarcoma: A case report. ( 29349900 )
2018
42
Eosinophilic Pustular Folliculitis Associated with Cutaneous Angiosarcoma. ( 29271395 )
2018
43
Cutaneous angiosarcoma: report of three different and typical cases admitted in a unique dermatology clinic. ( 28538886 )
2017
44
Primary Hepatic Angiosarcoma Mimicking Multifocal Liver Abscess with Disseminated Intravascular Coagulation and Hemoperitoneum. ( 28680781 )
2017
45
Clinicopathological features of breast angiosarcoma: A 16-years single-institution experience. ( 28704748 )
2017
46
Primary ovarian angiosarcoma in a 12- year -old girl: a case report of an exceptional localization in a context of limited resources country. ( 28852325 )
2017
47
Comprehensive profiling of H-Ras signalling in angiosarcoma endothelium. ( 28691211 )
2017
48
Innovative application of intraoperative laser-assisted fluorescence angiography in resection of an angiosarcoma of the scalp. ( 28943057 )
2017
49
Survivin: A novel marker and potential therapeutic target for human angiosarcoma. ( 28845553 )
2017
50
Primary breast angiosarcoma in young women from the same geographic region in a short period of time: Only a coincidence or an increased risk? ( 28597488 )
2017

Variations for Angiosarcoma

ClinVar genetic disease variations for Angiosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_004985.4(KRAS): c.57G> C (p.Leu19Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs121913538 GRCh38 Chromosome 12, 25245328: 25245328
2 KRAS NM_004985.4(KRAS): c.57G> C (p.Leu19Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs121913538 GRCh37 Chromosome 12, 25398262: 25398262
3 KRAS NM_004985.4(KRAS): c.57G> T (p.Leu19Phe) single nucleotide variant Likely pathogenic rs121913538 GRCh37 Chromosome 12, 25398262: 25398262
4 KRAS NM_004985.4(KRAS): c.57G> T (p.Leu19Phe) single nucleotide variant Likely pathogenic rs121913538 GRCh38 Chromosome 12, 25245328: 25245328

Expression for Angiosarcoma

Search GEO for disease gene expression data for Angiosarcoma.

Pathways for Angiosarcoma

Pathways related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 FLT1 FLT4 KDR KIT KRAS MUC1
2
Show member pathways
13.64 FLT1 FLT4 KDR KIT KRAS MYC
3
Show member pathways
13.41 KDR KIT KRAS KRT8 TEK VEGFA
4
Show member pathways
13.41 FLT1 FLT4 KDR KIT KRAS MYC
5
Show member pathways
13.26 KIT KRAS MUC1 MYC TEK VEGFA
6
Show member pathways
13.25 FLT1 FLT4 KDR KIT KRAS TEK
7
Show member pathways
13.22 FLT1 FLT4 KDR KIT KRAS TEK
8
Show member pathways
13.19 FLT1 FLT4 KDR KIT KRAS TEK
9
Show member pathways
12.98 FLT1 FLT4 KDR KIT KRAS
10
Show member pathways
12.97 FLT1 FLT4 KDR KIT KRAS
11
Show member pathways
12.87 FLT1 FLT4 KDR KIT TEK
12
Show member pathways
12.83 FLT1 FLT4 KDR KRAS VEGFA VWF
13 12.76 FLT4 KIT KRAS MYC VEGFA
14
Show member pathways
12.74 FLT1 FLT4 KDR KIT KRAS MYC
15
Show member pathways
12.66 FLT1 FLT4 KDR KIT KRAS TEK
16 12.59 FLT1 FLT4 KDR KIT KRAS MYC
17 12.45 KRAS MYC VEGFA VIM
18
Show member pathways
12.43 FLT1 FLT4 KDR KRAS
19
Show member pathways
12.38 FLT1 FLT4 KDR KRAS
20
Show member pathways
12.36 FLT1 FLT4 KDR KRAS VEGFA
21
Show member pathways
12.33 FLT1 FLT4 KDR VEGFA
22 12.23 KDR KRAS MYC VEGFA
23
Show member pathways
12.18 FLT1 KDR KRAS VEGFA
24 12.09 FLT1 FLT4 KDR KRAS MYC TEK
25 12.08 FLT1 FLT4 KDR KIT TEK
26
Show member pathways
12.02 FLT1 FLT4 KDR KRAS MYC
27 12.02 KDR MYC PROX1 VEGFA VIM
28 12.01 KDR PECAM1 VEGFA
29 11.93 MUC1 MYC VEGFA VIM
30
Show member pathways
11.92 FLT1 KDR VEGFA
31 11.85 FLT1 TEK VEGFA
32
Show member pathways
11.82 FLT1 FLT4 KDR VEGFA
33
Show member pathways
11.82 FLT1 FLT4 KDR KRAS MYC TEK
34
Show member pathways
11.81 KIT MYC VEGFA
35 11.79 FLT1 TEK VEGFA
36
Show member pathways
11.75 FLT1 FLT4 KDR KIT KRAS
37 11.69 KRAS MYC VEGFA
38 11.62 KIT KRAS MYC
39
Show member pathways
11.62 FLT1 FLT4 KDR KIT
40 11.47 KRAS MYC VEGFA
41 11.31 FLT1 KDR VEGFA
42 11.12 FLT1 FLT4 KDR PECAM1 PROX1 TEK
43 11.09 FLT1 KDR TEK VEGFA
44 11.06 FLT1 FLT4 KDR KRAS MYC VEGFA
45
Show member pathways
10.87 FLT1 FLT4 KDR VEGFA

GO Terms for Angiosarcoma

Cellular components related to Angiosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.93 FLT1 FLT4 KDR KIT KRAS KRT8
2 focal adhesion GO:0005925 9.56 FLT1 KRAS TEK VIM
3 membrane raft GO:0045121 9.26 KDR KRAS PECAM1 TEK
4 receptor complex GO:0043235 9.02 FLT1 FLT4 KDR KIT TEK

Biological processes related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 FLT1 FLT4 KDR KIT TEK
2 angiogenesis GO:0001525 9.98 FLT1 FLT4 KDR TEK VEGFA
3 negative regulation of apoptotic process GO:0043066 9.98 FLT1 FLT4 KDR KIT MYC TEK
4 MAPK cascade GO:0000165 9.96 KIT KRAS MYC TEK
5 positive regulation of cell migration GO:0030335 9.95 FLT1 KDR KIT VEGFA
6 protein autophosphorylation GO:0046777 9.95 FLT1 FLT4 KDR KIT TEK
7 cytokine-mediated signaling pathway GO:0019221 9.93 KIT KRAS MUC1 MYC VEGFA VIM
8 positive regulation of angiogenesis GO:0045766 9.92 FLT1 KDR TEK VEGFA
9 peptidyl-tyrosine phosphorylation GO:0018108 9.92 FLT1 FLT4 KDR KIT TEK
10 positive regulation of protein phosphorylation GO:0001934 9.89 FLT4 KDR KRAS TEK VEGFA
11 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.88 FLT1 FLT4 KDR VEGFA
12 positive regulation of MAPK cascade GO:0043410 9.88 FLT1 FLT4 KDR KIT TEK
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.87 FLT1 KDR KIT TEK
14 platelet degranulation GO:0002576 9.86 PECAM1 VEGFA VWF
15 positive regulation of MAP kinase activity GO:0043406 9.86 FLT1 KIT KRAS VEGFA
16 vasculogenesis GO:0001570 9.84 FLT1 FLT4 KDR VEGFA
17 ovarian follicle development GO:0001541 9.8 KIT MYC VEGFA
18 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 FLT1 FLT4 KDR KIT TEK
19 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.79 FLT1 KIT TEK
20 sprouting angiogenesis GO:0002040 9.78 FLT1 FLT4 TEK
21 positive regulation of focal adhesion assembly GO:0051894 9.77 KDR TEK VEGFA
22 negative regulation of signal transduction GO:0009968 9.77 FLT1 FLT4 KDR KIT TEK
23 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.69 FLT1 VEGFA
24 vascular endothelial growth factor signaling pathway GO:0038084 9.69 FLT1 FLT4 KDR
25 embryonic hemopoiesis GO:0035162 9.68 KDR KIT
26 cell migration involved in sprouting angiogenesis GO:0002042 9.68 KDR VEGFA
27 megakaryocyte development GO:0035855 9.68 FLI1 KIT
28 positive regulation of positive chemotaxis GO:0050927 9.67 KDR VEGFA
29 lymph vessel development GO:0001945 9.67 FLT4 PROX1
30 lymphangiogenesis GO:0001946 9.66 FLT4 PROX1
31 positive regulation of phospholipase C activity GO:0010863 9.65 FLT1 KIT
32 positive regulation of protein kinase C signaling GO:0090037 9.65 FLT4 VEGFA
33 positive regulation of kinase activity GO:0033674 9.65 FLT1 FLT4 KDR KIT TEK
34 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.64 KDR VEGFA
35 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.62 FLT1 FLT4 KDR VEGFA
36 positive regulation of cell proliferation GO:0008284 9.56 FLT1 FLT4 KDR KIT KRAS MYC
37 positive regulation of endothelial cell proliferation GO:0001938 9.55 FLT4 KDR PROX1 TEK VEGFA
38 positive regulation of endothelial cell migration GO:0010595 9.02 FLT4 KDR PROX1 TEK VEGFA
39 multicellular organism development GO:0007275 10.18 FLT1 FLT4 KDR KIT PROX1 TEK
40 cell differentiation GO:0030154 10.16 FLI1 FLT1 FLT4 KDR KIT TEK
41 phosphorylation GO:0016310 10.08 FLT1 FLT4 KDR KIT TEK
42 protein phosphorylation GO:0006468 10.07 FLT1 FLT4 KDR KIT TEK
43 positive regulation of gene expression GO:0010628 10.03 KIT KRAS MYC VEGFA VIM

Molecular functions related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.89 FLT1 FLT4 KDR KIT TEK
2 protein kinase activity GO:0004672 9.85 FLT1 FLT4 KDR KIT TEK
3 transmembrane signaling receptor activity GO:0004888 9.83 FLT1 FLT4 KDR KIT TEK
4 protein tyrosine kinase activity GO:0004713 9.77 FLT1 FLT4 KDR KIT TEK
5 MAP kinase kinase kinase activity GO:0004709 9.65 FLT1 FLT4 KDR KIT TEK
6 mitogen-activated protein kinase kinase binding GO:0031434 9.55 FLT1 FLT4 KDR KIT TEK
7 vascular endothelial growth factor-activated receptor activity GO:0005021 9.5 FLT1 FLT4 KDR
8 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.48 KDR KIT
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.35 FLT1 FLT4 KDR KIT TEK
10 growth factor binding GO:0019838 9.02 FLT1 FLT4 KDR KIT TEK
11 protein binding GO:0005515 10.28 FLI1 FLT1 FLT4 KDR KIT KRAS

Sources for Angiosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....